文献速递白血病贫血与红细胞疾病

高原地区新诊断急性白血病的临床特征与治疗疗效

[Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析西藏自治区人民医院2010年2月至2023年4月收治的105例急性白血病患者临床资料,包括24例ALL、62例AML及19例无系别资料者。ALL、APL、AML(非APL)一疗程诱导后完全缓解率分别为57.1%(8/14)、100%(6/6)、53.6%(15/28)。近年收治患者EFS及OS呈改善趋势,但疗效与国内发达地区仍有差距。

要点

  • 105例中ALL 24例、AML 62例、无系别资料19例,AML以FAB M2为主(25/57)。
  • ALL、APL、AML(非APL)一疗程CR率分别为57.1%、100%、53.6%。
  • CBF-AML中位EFS 10个月、OS 13个月,非CBF-AML中位EFS及OS均2个月(P<0.01)。

核心结论

  • 高原地区急性白血病疗效较国内发达地区仍有差距,但近年来已取得较大进展。
  • 推进急性白血病精准诊断和治疗有利于改善患者预后。

研究设计与样本

  • 回顾性分析2010年2月至2023年4月西藏自治区人民医院收治的急性白血病患者临床资料。
  • 共纳入105例急性白血病患者,包括ALL 24例、AML 62例、无系别资料19例。
  • 收集血常规、细胞形态学、流式细胞术免疫分型、分子生物学及细胞遗传学等资料并进行生存分析。

主要发现

  • 11例具备流式免疫分型资料的ALL患者均为B-ALL;57例有分型资料的AML以M2为主(25例),其次为APL 12例、M5 6例、M4EO 5例、M1 4例、M4 4例、M0 1例。
  • 可评价疗效者48例,ALL 14例、APL 6例、AML(非APL)28例,一疗程诱导后CR率分别为57.1%(8/14)、100%(6/6)、53.6%(15/28)。
  • 中位随访37(95%CI 17~57)个月,ALL中位EFS 2(95%CI 0~9)个月、中位OS 3(95%CI 0~9)个月;APL中位EFS及OS未达到。
  • CBF-AML中位EFS 10(95%CI 0~21)个月、OS 13(95%CI 3~23)个月;非CBF-AML中位EFS及OS均为2(95%CI 1~3)个月,不同亚型AML的EFS及OS差异有统计学意义(P值均<0.01)。
  • ALL 2020-2023年组较2010-2019年组EFS(10个月对1个月,P=0.16)及OS(15个月对1个月,P=0.10)呈改善趋势;AML 2016-2023年组较2010-2015年组EFS(10个月对3个月,P=0.27)及OS(12个月对3个月,P=0.12)呈改善趋势。

临床怎么用

  • 作者认为推进急性白血病精准诊断和治疗有利于改善患者预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to retrospectively analyze the clinical characteristics and prognosis of patients with acute leukemia in the plateau. Methods: The clinical information of patients diagnosed with acute leukemia from February 2010 to April 2023 at the People's Hospital of Tibet Autonomous Region was reviewed and collected, including blood cell count, morphology, immunophenotype, cytogenetics, and molecular data. Survival analysis was conducted to analyze the outcome of patients with acute leukemia. Results: This study enrolled 105 patients with acute leukemia, including 24 with acute lymphoblastic leukemia (ALL), 62 with acute myeloid leukemia (AML), and 19 with acute leukemia without baseline data. Of the patients with ALL, 11 underwent bone marrow testing for immunophenotype, all of whom were B-cell lineage. The main FAB subtype of patients with AML was M(2) (25/57), followed by M(3) (12/57), M(5) (6/57), M(4EO) (5/57), M(1) (4/57), M(4) (4/57), and M(0) (1/57). The complete remission rates of patients with ALL, acute promyelocytic leukemia (APL), and AML (non-APL) after one course of induction therapy were 57.1% (8/14), 100% (6/6), and 53.6% (15/28), respectively. The median event-free survival (EFS) and overall survival (OS) for patients with ALL were 2 (95% CI 0-9) and 3 (95% CI 0-9) months, respectively, with a median followup of 37 (95% CI 17-57) months. Patients with APL did not reach median EFS or OS, whereas the median EFS and OS for core binding factor AML (CBF-AML) cases were 10 (95% CI 0-21) months and 13 (95% CI 3-23) months, respectively, and patients with non-CBF-AML had inferior median EFS (2 months, 95% CI 1-3) and OS (2 months, 95% CI 1-3) (P<0.01). Patients with ALL treated from 2020 to 2023 demonstrated trends toward better EFS (P=0.16) and OS (P=0.10) than those treated from 2010 to 2019. Similarly, trends toward superior EFS (P=0.27) and OS (P=0.12) were observed in patients with AML treated from 2016 to 2023, in comparison with those treated from 2010 to 2015. Conclusion: Progress in the treatment and prognosis of patients with acute leukemia in the plateau has been observed in recent years, which can be further promoted by precision diagnosis and tailored regimens. 目的: 描述及分析高原地区急性白血病患者的临床特征及疗效。 方法: 回顾性统计分析2010年2月至2023年4月西藏自治区人民医院收治的急性白血病患者的临床资料,包括血常规、细胞形态学、流式细胞术免疫分型、分子生物学及细胞遗传学等,对患者进行随访,并进行生存分析。 结果: 研究共纳入105例急性白血病患者,包括急性淋巴细胞白血病(ALL)24例、急性髓系白血病(AML)62例,无系别资料的急性白血病患者19例。11例具备流式细胞术免疫分型资料的ALL患者均为B-ALL。57例AML患者具有分型资料FAB亚型以M(2)为主(25例),其次为急性早幼粒细胞白血病12例,M(5) 6例,M(4EO) 5例,M(1) 4例,M(4) 4例,M(0) 1例。经1个疗程诱导化疗后可评价疗效者48例,其中ALL 14例,APL 6例,AML(非APL)28例,完全缓解(CR)率分别为57.1%(8/14)、100%(6/6)、53.6%(15/28)。中位随访37(95%CI 17~57)个月,ALL患者的中位无事件生存(EFS)期为2(95%CI 0~9)个月,中位总生存(OS)期为3(95%CI 0~9)个月;APL患者中位EFS期及OS期未达到;核心结合因子相关AML(CBF-AML)患者的中位EFS期及OS期分别为10(95%CI 0~21)个月、13(95%CI 3~23)个月,非CBF-AML(包括无染色体核型及融合基因资料患者)患者的中位EFS期及OS期均为2(95%CI 1~3)个月,不同亚型AML患者的EFS期及OS期差异有统计学意义(P值均<0.01)。按收治年份将ALL患者分成2010-2019年和2020-2023年两组,后者较前者EFS(10个月对1个月,P=0.16)及OS(15个月对1个月,P=0.10)呈改善趋势;按收治年份将AML患者分成2010-2015年和2016-2023年两组,后者较前者EFS(10个月对3个月,P=0.27)及OS(12个月对3个月,P=0.12)呈改善趋势。 结论: 高原地区急性白血病疗效虽然较国内发达地区仍有差距,但近年来已取得了较大进展,推进急性白血病精准诊断和治疗有利于改善患者预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. He QY, Lai AL, Zhang A, et al. [Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39765351. doi:10.3760/cma.j.cn121090-20240514-00182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。